Valuation dashboard for Praxis Precision Medicines, Inc. (PRAX) with P/E N/A, P/B 6.34, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
Balance sheet quality for PRAX: current ratio of 10.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 6.34 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRAX | Praxis Precision Medicines, Inc. | $8.6B | 6.34 | ||
| KYMR | Kymera Therapeutics, Inc. | $9.6B | 7.56 | ||
| CNTA | Centessa Pharmaceuticals plc | $6.3B | 12.76 | -60.4% | |
| IMVT | Immunovant, Inc. | $7.5B | 9.99 | ||
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% | |
| LGND | Ligand Pharmaceuticals Incorporated | $5.5B | 27.12 | 5.63 | |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.7B | 12.24 | 3.62 | |
| SLNO | Soleno Therapeutics, Inc. | $2.8B |
Price
| Price | $308.99 |
| Market Cap | $8.6B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACAD · AKRO · CNTA · CRNX · IMVT · KYMR · LGND
Explore sector: Healthcare · Biotechnology
More sections of PRAX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks